ABBV.NEO AbbVie CDR (CAD Hedged)
- Market cap
- CAD 712B
- P/E
- 205.5x
- P/B
- 48.72x
- ROE
- -
- Dividend yield
- 2.95%
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ABBV.NEO undervalued?
Graham numberThe Graham number of AbbVie CDR (CAD Hedged) cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AbbVie CDR (CAD Hedged) fundamental analysis
5 of 22 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 1/1
Return on assets (6.4%) is above the industry median (3.8%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-1.4%) is below the industry median (14.7%).
Revenue Growth 1/2
Revenue grew 1.8% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 4.6x against interest expense, below 5x.
PE vs Market 0/1
PE (214.7x) is above the market median (20.3x).
PE vs Industry 0/1
PE (214.7x) is above the industry median (16.6x).
PBV 0/1
Price to book (50.9x) is above the industry median (1.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 10,930.7, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.3%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
Payout ratio is 275.8%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
AbbVie CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AbbVie CDR (CAD Hedged)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory di…
Full company profileAbbVie CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AbbVie CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 58.1B | 54.3B | 56.3B | 61.2B | 64.0B |
| Gross Profit | 40.6B | 33.9B | 39.4B | 43.0B | 47.0B |
| Operating Income | 18.8B | 13.5B | 11.9B | 20.1B | 22.9B |
| EBITDA | 24.2B | 17.2B | 14.9B | 17.6B | 21.2B |
| Net Income | 11.8B | 4.86B | 4.28B | 4.23B | 8.62B |
| EPS | 6.69 | 2.75 | 2.42 | 2.39 | 4.88 |
| Balance Sheet | |||||
| Total Assets | 139B | 135B | 135B | 134B | 135B |
| Total Liabilities | 122B | 124B | 132B | 137B | 141B |
| Shareholders' Equity | 17.3B | 10.4B | 3.33B | -3.27B | -5.94B |
| Cash & Short-term Investments | 9.20B | 12.8B | 5.52B | 5.23B | 6.57B |
| Cash Flow | |||||
| Operating Cash Flow | 24.9B | 22.8B | 18.8B | 19.0B | 14.5B |
| Capital Expenditure | 695M | 777M | 974M | 1.21B | 1.17B |
| Free Cash Flow | 24.2B | 22.1B | 17.8B | 17.8B | 13.4B |
| Ratios | |||||
| ROE | 68.6% | 46.9% | 128.7% | - | - |
| ROA | 8.5% | 3.6% | 3.2% | 3.2% | 6.4% |
| Net Profit Margin | 20.4% | 9.0% | 7.6% | 6.9% | 13.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AbbVie CDR (CAD Hedged) dividends
- Dividend yield
- 2.95%
- Forward dividend
- 0.95 CAD
- Payout ratio
- 275.8%
- Ex-dividend date
- Jan 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 11.7B | 6.59 | 275.8% |
| 2024 | USD 11.0B | 6.25 | 257.7% |
| 2023 | USD 10.5B | 5.97 | 216.7% |
| 2022 | USD 10.0B | 5.68 | 84.9% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AbbVie CDR (CAD Hedged)
Ownership data of AbbVie CDR (CAD Hedged) is not available yet.
AbbVie CDR (CAD Hedged) company profile
- Company name
- AbbVie CDR (CAD Hedged)
- Ticker
- ABBV.NEO
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 55,000
- Fiscal year end
- December
- Address
- 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
- Phone
- 847 932 7900
- Website
- abbvie.com
About AbbVie CDR (CAD Hedged)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie CDR (CAD Hedged) management
10- Mr. Robert A. Michael CPACEO & Chairman of the Board · born 1970
- Mr. Scott T. ReentsExecutive VP & CFO · born 1967
- Dr. Azita Saleki-Gerhardt Ph.D.Executive VP & COO · born 1963
- Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer · born 1969
- Dr. Roopal Thakkar M.D.Executive VP of Research and Development & Chief Scientific Officer · born 1972
- Ms. Elizabeth SheaSenior Vice President of Investor Relations
- Mr. Perry C. SiatisExecutive VP, General Counsel & Secretary · born 1975
- Mr. Demetris D. CrumExecutive VP & Chief Human Resources Officer
- Mr. Wulff-Erik von BorckeSenior VP & President of Oncology
- Dr. Nicholas J. Donoghoe M.D.Executive VP and Chief Business & Strategy Officer · born 1981